Volume 154, Issue 5, Pages (November 2018)

Slides:

Advertisements

Similar presentations

Date of download: 5/27/2016 From: Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan: A Parallel, Randomized Trial Ann Intern Med. 2013;158(9):

Advertisements

Copyright © 2003 American Medical Association. All rights reserved.

Volume 129, Issue 3, Pages (March 2006)

Volume 148, Issue 5, Pages (November 2015)

Volume 150, Issue 3, Pages (September 2016)

Volume 26, Issue 2, Pages e2 (August 2017)

Volume 149, Issue 6, Pages (June 2016)

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan Yoshio Taguchi, Masahito.

Volume 120, Issue 6, Pages (December 2001)

The treatment of pulmonary sarcoidosis

Single-Breath Washout Tests to Assess Small Airway Disease in COPD

Volume 152, Issue 3, Pages (September 2017)

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Volume 148, Issue 5, Pages (November 2015)

Volume 143, Issue 1, Pages (January 2013)

Volume 151, Issue 3, Pages (March 2017)

Volume 143, Issue 6, Pages (June 2013)

Volume 152, Issue 5, Pages (November 2017)

Volume 151, Issue 3, Pages (March 2017)

Volume 152, Issue 5, Pages (November 2017)

Volume 153, Issue 1, Pages (January 2018)

Volume 153, Issue 4, Pages (April 2018)

Volume 153, Issue 5, Pages (May 2018)

A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.

Volume 146, Issue 6, Pages (December 2014)

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

Volume 150, Issue 6, Pages (December 2016)

Volume 132, Issue 1, Pages (January 2007)

Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma

The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial Pierluigi Paggiaro,

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Volume 151, Issue 1, Pages (January 2017)

Volume 153, Issue 3, Pages e41-e43 (March 2018)

Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment.

Volume 151, Issue 5, Pages e99-e102 (May 2017)

A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Volume 152, Issue 6, Pages (December 2017)

A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies Linda.

Volume 153, Issue 6, Pages (June 2018)

Volume 151, Issue 3, Pages (March 2017)

Effectiveness of glucosamine for symptoms of knee osteoarthritis: Results from an internet-based randomized double-blind controlled trial Timothy McAlindon,

An Elderly Man With Dyspnea and Chest Pain

Safety and Efficacy of Budesonide Oral Suspension Maintenance Therapy in Patients With Eosinophilic Esophagitis Evan S. Dellon, David A. Katzka, Margaret.

Kevin Murphy, MD, Joshua Jacobs, MD, Leif Bjermer, MD, John M

Solriamfetol for the Treatment of Excessive Sleepiness in OSA

Regional Emphysema Score Predicting Overall Survival, Quality of Life, and Pulmonary Function Recovery in Early-Stage Lung Cancer Patients Jie Dai, PhD,

Ronnie Fass, Stephen J. Sontag, Barry Traxler, Mark Sostek

Modelled mean (SEM) observed forced vital capacity (FVC) volume change from baseline (mL) over time by dose intensity (>90%, ≤90%), based on actual dose.

Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease:

Volume 155, Issue 4, Pages (April 2019)

A phase I clinical study of inhaled nitric oxide in healthy adults

Trial in Progress: Gravitas-301, a Randomized, Double-Blind Phase 3 Study of Itacitinib or Placebo with Corticosteroids (CS) for the First-Line Treatment.

International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients Drucy Borowitz, Christopher Stevens,

Volume 26, Issue 2, Pages e2 (August 2017)

Volume 155, Issue 1, Pages (January 2019)

Volume 103, Issue 6, Pages (June 1993)

Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results.

Bedside Calibration Of Pulmonary Artery Catheters

Volume 146, Issue 6, Pages (December 2014)

Hemodynamic Thresholds for Precapillary Pulmonary Hypertension

Volume 150, Issue 4, Pages (October 2016)

David Bédard Méthot, MD, Évelyne Leblanc, MD, Yves Lacasse, MD CHEST

Volume 128, Issue 4, Pages (April 2005)

Eckard Hamelmann, MD, Eric D

Ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain: a randomized controlled.

A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication Eric P. Brass, MD,

Michael Kreuter, MD, David J

Mohmmed Algamdi, MBBS, Mohsen Sadatsafavi, PhD, Jolene H

Presentation transcript:

Volume 154, Issue 5, Pages 1061-1069 (November 2018) Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis Scott M. Palmer, MD, Laurie Snyder, MD, Jamie L. Todd, MD, Benjamin Soule, MD, Rose Christian, MD, Kevin Anstrom, PhD, Yi Luo, PhD, Robert Gagnon, PhD, Glenn Rosen, MD CHEST Volume 154, Issue 5, Pages 1061-1069 (November 2018) DOI: 10.1016/j.chest.2018.08.1058 Copyright © 2018 The Authors Terms and Conditions

Figure 1 Study flow. AE = adverse event; qd = once daily. aA total of 182 screened patients failed screening and were not randomized. bThe study was terminated early, and the last 10 patients were withdrawn after the sponsor's decision to stop the study because of concerns regarding potential gallbladder toxicity noted in three patients. CHEST 2018 154, 1061-1069DOI: (10.1016/j.chest.2018.08.1058) Copyright © 2018 The Authors Terms and Conditions

Figure 2 Change in FVC from baseline to week 26 (intent-to-treat population). *P < .05 vs placebo as assessed by a linear mixed-model repeated-measures analysis adjusted for age, sex, and height. See Figure 1 legend for expansion of abbreviation. CHEST 2018 154, 1061-1069DOI: (10.1016/j.chest.2018.08.1058) Copyright © 2018 The Authors Terms and Conditions

Figure 3 A-C, Change in quantitative lung fibrosis (A), dyspnea (B), and lung fibrosis (C) from baseline to week 26 (intent-to-treat population). *From an analysis of variance with age, sex, and height as covariates; the output was backtransformed to obtain results in terms of the ratio of week 26 to baseline. Dlco = diffusing capacity for carbon monoxide. See Figure 1 legend for expansion of other abbreviation. CHEST 2018 154, 1061-1069DOI: (10.1016/j.chest.2018.08.1058) Copyright © 2018 The Authors Terms and Conditions

Figure 4 Changes in biomarkers of interest related to fibrosis and inflammation. See Figure 1 legend for expansion of abbreviation. CHEST 2018 154, 1061-1069DOI: (10.1016/j.chest.2018.08.1058) Copyright © 2018 The Authors Terms and Conditions